MannKind Corporation (NASDAQ:MNKD) Looks Inexpensive But Perhaps Not Attractive Enough
MannKind Corporation's (NASDAQ:MNKD) price-to-sales (or "P/S") ratio of 7.3x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
Reported Earlier, MannKind's Inhaled Insulin Afrezza Shows Results in 17-Week Study
MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today a
Express News | MannKind Corp: More People Met Glycemic Target of a1C (Less Than 7%) With Afrezza, Few Subjects Worsened Switching From Usual Care to Inhaled Insulin
Express News | MannKind Corp: Inhale-3 Study Proves Inhaled Insulin Is as Effective as Usual Care for Adults Living With T1D,Meeting Primary Endpoint
Express News | MannKind Corp: Announced Positive 17-Week Results From Inhale-3 Study, Evaluating Afrezza (Plus Basalinsulin) Vs. Usual Care
Express News | MannKind Corp: More Than 50% of Subjects at End of Inhale-3 Study Expressed Interest in Continuing to Use Afrezza
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin Vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients ut
Recent 5.2% Pullback Isn't Enough to Hurt Long-term MannKind (NASDAQ:MNKD) Shareholders, They're Still up 327% Over 5 Years
MannKind Initiated at Buy by Rodman & Renshaw
MannKind Initiated at Buy by Rodman & Renshaw
Express News | Rodman & Renshaw Initiates Coverage On MannKind With Buy Rating, Announces Price Target of $8
Rodman & Renshaw Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $8
Rodman & Renshaw analyst Elemer Piros initiates coverage on $MannKind(MNKD.US)$ with a buy rating, and sets the target price at $8.According to TipRanks data, the analyst has a success rate of 37.3% a
Inhale-3 Study Results to Be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions
17-week endpoint results comparing Afrezza head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver
Express News | Pulmatrix Enters Cross License Agreement With MannKind To Use Cricket Inhalation Device For Delivery Of PUR3100 And Other Dry Powder Formulations For Neurological Diseases
Express News | Pulmatrix Inc - as Part of Transaction, MannKind Will Assume Lease of Bedford, Mass., R&D Facility
Express News | Pulmatrix Inc - Assumption of Our Lease and Laboratory by MannKind Helps Extend Our Cash Runway Further Into 2026
Express News | Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space Non-cash deal includes royalty-free iSPERSE technology license in exchange for